Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ganciclovir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Ganciclovir. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-003312-30 Sponsor Protocol Number: 2012-24 Start Date*: 2012-12-12
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Interest of preemptive treatment with ganciclovir or acyclovir in patients requiring prolonged mechanical ventilation and have either a cytomegalovirus replication in blood or an herpes simplex vir...
    Medical condition: mechanically ventilated patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020551-31 Sponsor Protocol Number: NBMT-CMV Start Date*: 2004-09-29
    Sponsor Name:Nordic Bone and Marrow Transplantation Group
    Full Title: Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation.
    Medical condition: First cytomegalovirus DNAemia after stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063310 Cytomegalovirus DNA test positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002233-11 Sponsor Protocol Number: ELISPOT-TC Start Date*: 2020-01-16
    Sponsor Name:Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge
    Full Title: The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection...
    Medical condition: We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10058666 Cytomegalovirus infection reactivation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002603-15 Sponsor Protocol Number: GANCMV-2011 Start Date*: 2011-11-21
    Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA
    Full Title: Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Medical condition: Active infection with cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004745-28 Sponsor Protocol Number: V.1.1 Start Date*: 2008-09-04
    Sponsor Name:Medizinische Universität Wien, KIM III, Abteilung für Nephrologie
    Full Title: Certican (Everolimus®) against Cytomegalovirus Disease in Renal Transplant Patients
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004725-13 Sponsor Protocol Number: SHP620-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Shire ViroPharma Incorporated
    Full Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients...
    Medical condition: CMV infections resistant or refractory in transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    20.0 100000004862 10021829 Infection in solid organ transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) AT (Completed) HR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004729-16 Sponsor Protocol Number: 1263-301 Start Date*: 2008-01-25
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of oral Maribavir versus oral Ganciclovir to prevent cytomegalovirus disease in recipients of orthotopic liver transplants at h...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002319-41 Sponsor Protocol Number: HULP-VIR-2014-01 Start Date*: 2015-05-11
    Sponsor Name:Ana Boto de los Bueis
    Full Title: Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis.
    Medical condition: Acute adenoviral conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10001257 Adenoviral conjunctivitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003587-34 Sponsor Protocol Number: IPR/01 Start Date*: 2007-04-12
    Sponsor Name:MolMed
    Full Title: A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with hae...
    Medical condition: Hematological malignancies at high risk of relapse based on disease progression or presence of negative prognostic factor, who have received a HCTfrom donor HLA mismatched (haploidentical) for 2 o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001055-30 Sponsor Protocol Number: MK8228-002 Start Date*: 2018-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovir...
    Medical condition: Prevention of CMV disease in D+/R- kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015965-29 Sponsor Protocol Number: ML 22371 Start Date*: 2010-05-17
    Sponsor Name:Pierrel Research Europe GmbH
    Full Title: Multicenter, randomized study comparing oral valganciclovir versus intravenous ganciclovir in patients following allogeneic stem cell transplantation
    Medical condition: Patients with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after allogeneic SCT.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011831 Cytomegalovirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000464-28 Sponsor Protocol Number: 904 Start Date*: 2005-01-20
    Sponsor Name:Ark Therapeutics Limited
    Full Title: A Controlled, Randomised, Parallel Group, Multicentre Study of the Efficacy and Safety of Herpes Simplex Virus-Thymidine Kinase Gene Therapy (CereproTM), with Subsequent Ganciclovir, for the Treatm...
    Medical condition: Operable high grade primary or recurrent glioma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10018338 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) FI (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002912-15 Sponsor Protocol Number: CHUBX2016/40 Start Date*: 2017-10-03
    Sponsor Name:CHU de Bordeaux
    Full Title: Secondary Prophylaxis after CMV disease in Kidney transplant patients targeted by γδ T cells immunomonitoring.
    Medical condition: Kidney transplants patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002813-19 Sponsor Protocol Number: TAMOVALCIR Start Date*: 2005-11-11
    Sponsor Name:Fundación Pethema
    Full Title: “Estudio en fase II, multicentrico, prospectivo, abierto, de tratamiento anticipado con valganciclovir de la infección por citomegalovirus en el transplante alogénico de progenitores hematopoyético ”.
    Medical condition: Tratamiento anticipado de la infección por CMV (detectada en sangre) en un grupo de receptores de TPH alogénico homogéneamente tratados
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000911-25 Sponsor Protocol Number: BST-LT-01 Start Date*: 2019-02-12
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi...
    Medical condition: CMV viral infection in an immunocompromised host
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024646-30 Sponsor Protocol Number: CCCC_CMV_protocol Start Date*: 2011-03-22
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care.
    Medical condition: reactivation of cytomegalovirus infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005197-10 Sponsor Protocol Number: VT3996-202 Start Date*: 2021-10-01
    Sponsor Name:Viracta Therapeutics, Inc.
    Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
    Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071441 Epstein-Barr virus associated lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021172-28 Sponsor Protocol Number: NP22523 Start Date*: 2010-10-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transpl...
    Medical condition: Prevención de la enfermedad por CMV en receptores de trasplantes de órganos sólidos Prevention of CMV disease in solid organ transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009701 CMV LLT
    12.1 10049107 CMV viraemia LLT
    12.1 10060577 CMV viremia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001449-34 Sponsor Protocol Number: CMV-INMUNOGUIA Start Date*: 2011-08-19
    Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA
    Full Title: Phase II study, multicenter, prospective, open label, preemptive treatment of cytomegalovirus (CMV) infection driven by virologic monitoring and quantification of T CD8pp65/IE-1-IFNgamma+ lymphocyt...
    Medical condition: Cytomegalovirus infection in patients treated with hematopoietic allogenic transplant
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003472-19 Sponsor Protocol Number: version 4.0, 31 May 2007 Start Date*: 2007-09-13
    Sponsor Name:Royal Free Hampstead NHS Trust
    Full Title: Determining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring.
    Medical condition: Transplant recipients with CMV infection.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:24:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA